The Interdisciplinary Nanoscience Center at Aarhus University: News

Mingdong Dong and Jeppe Vang Lauritsen have been appointed Professors in Experimental Surface and Interface Science. (Photos by Maria Randima and Lars Kruse, AU Photo)

26 March 2021 - iNano

Congratulations to Mingdong Dong and Jeppe Vang Lauritsen who have been appointed Professors in Experimental Surface and Interface Science at the…

Alexander Zelikin will be appointed as Professor at Dept. of Chemistry on 1 April 2021. (Photo: Lars Kruse, AU Photo)

26 March 2021 - iNano

Congratulations to Alexander Zelikin who has been appointed Professor at Department of Chemistry, Faculty of Natural Sciences, Aarhus University. The…

Professor Daniel Otzen and Assistant Professor Alonso Rosas-Hernandez are among the new AIAS Associates. Photo: Jesper Rais (DO), Private (ARH)

25 March 2021 - iNano

Congratulations to Professor Daniel Otzen (iNANO and MBG) and Assistant Professor Alonso Rosas-Hernández (CHEM and iNANO) who are among the new AIAS…

iNANO researcher Mingdong Dong reports of filamentous Gram-positive bacterium for long-distance electron transfer in Nature Communications. (Image: Nature Commun 12, Article no. 1709 (2021)

19 March 2021 - iNano

Increasing evidence has demonstrated how the microbial world is electrically connected. Electrical wire networks on the micrometer to centimeter scale…

Associate Professor Ken Howard receives this year’s award for the best paper in the Journal of Controlled Release. (Photo: Maria Randima, AU Photo)

18 March 2021 - iNano

Associate Professor Ken Howard has received the award for best paper of in the Journal of Controlled Release awarded by the Controlled Release Society…

BettaSensing, co-founded by iNANO researcher Noga Gal, is developing a flavor fingerprint technology. Photo: Mathilde Kræmer.

18 March 2021 - iNano

How do we know, if our food tastes good, or if it has already gone bad? The startup BettaSensing, co-founded by iNANO researcher Noga Gal, has created…

Associate Professor Ken Howard and his research team join forces with world leading scientists to develop new platform for tunable immunotherapy. (Image: Nature Commun Biol 4, Article no. 310 (2021))

11 March 2021 - iNano

AU researchers join forces with world leaders to develop a new albumin-based platform for long-acting, efficient, and safer immunotherapy. Assoc.…

Jørgen Kjems (left) and Morten Venø are partners in a new consortium, PRIME, that will seek to develop biological nano-implants - based on naturally occurring signaling pathways - that can help patients with epilepsy. Photo: Anne Færch Nielsen.

11 March 2021 - iNano

Epilepsy is one of the most common neurological diseases and seizures can be debilitating. Unfortunately, treatments to prevent these seizures are…

Unraveling the three-dimensional structure of the glycine transporter, researchers have now come a big step closer to understanding the regulation of glycine in the brain. These result open up opportunities to find effective drugs that inhibit GlyT1 funct

04 March 2021 - iNano

Glycine can stimulate or inhibit neurons in the brain, thereby controlling complex functions. Unraveling the three-dimensional structure of the…

Aerial photo og Aarhus University by Jørgen Weber

03 March 2021 - iNano

The Novo Nordisk Foundation has for the first time granted project support earmarked for basic research in the natural sciences and technical…

Interdisciplinary Nanoscience Center

News

Professor Appointments

Professor Appointment

Daniel Otzen and Alonso Rosas-Hernández among new AIAS Associates

Filamentous Gram-positive bacterium for long-distance electron

Prestigious Best Paper award to iNANO researcher

Flavor recognition technology on its way to the market. Is your startup company next?

Albumin solution to an unmet need in cancer immunotherapy

Developing biological nano-implants to block epileptic seizures

Structure determination of the glycine transporter GlyT1 opens new avenues in development of psychiatric drugs

iNANO afiliated researchers receive new grants from the Novo Nordisk Foundation